Overview

Detailed Summary

Senores Pharmaceuticals Limited primarily engages in developing and manufacturing pharmaceuticals for regulated markets such as the US and Canada, along with emerging markets. It has built a robust regimen of ANDAs, facilitating entry in niche, high-complexity therapeutic areas.
Significantly increased its portfolio to 46 approved ANDAs covering 137 strengths, reflecting a scaling up of operations and strategic market penetration. Expected launches from pending ANDAs promise further growth.
The acquisition of a 75% stake in Apnar Pharmaceuticals has strengthened Senores' operational footprint in regulated markets, with benefits of existing approvals for generic formulations.
The company has shown tremendous financial growth, evidenced by a 64% increase in total income in Q3FY26 YoY, supported by a focused strategy on regulated and emerging markets.
Senores merges traditional pharma with modern strategies such as CDMO/CMO, optimizing both generic and branded sectors with increasing EBITDA margins through focused commercial plans.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 6,048 Cr
Volatility: Moderate Risk
P/E Ratio: 52.4
Industry P/E: 37.2
PEG Ratio: 1.6
P/B Ratio: 7.0
52W High: 1,509.20
52W Low: 631.00

Sales CAGR

1Y: 85.65%
3Y: 41.70%
5Y: —
10Y: —

Profit CAGR

1Y: 78.36%
3Y: 75.57%
5Y: —
10Y: —

ROE

TTM: 12.36%
3Y: 0.62%
5Y: 0.75%
10Y: —

ROCE

TTM: 14.43%
3Y: 1.94%
5Y: 2.02%
10Y: —

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
JSLL		569.15	7,075 Cr	31.89	15.15	0.79	47.50	52.11	32.88
SPARC		215.00	6,974 Cr	4.49	5.21	0.00	116.01	80.89	71.55
SUPRIYA		845.50	6,799 Cr	32.51	5.68	0.12	17.46	23.00	15.41
FDC		417.80	6,794 Cr	24.14	2.73	1.20	11.32	15.18	9.64
SENORES		1411.50	6,500 Cr	56.34	6.96	0.00	12.36	14.43	7.58
AARTIPHARM		685.65	6,217 Cr	33.34	2.93	0.51	8.22	9.59	5.36
INNOVACAP		975.00	5,527 Cr	39.22	5.07	0.21	12.92	14.30	7.67
Median: 7 Co.	—	685.65	6,794 Cr	32.51	5.21	0.21	12.92	15.18	9.64

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	102	80	101	103	114	138	162	175	175	180
Expenses	80	59	77	77	95	104	112	121	128	126
Operating Profit	22	21	23	26	19	34	50	54	47	54
OPM %	21.86	26.52	23.12	24.94	17.02	24.76	30.61	30.94	27.11	29.83
Other Income	1.96	0.48	1.86	5.16	12	3.36	5.41	3.78	18	2.81
Interest	3.03	4.82	5.27	6.16	5.30	5.04	6.19	5.33	8.46	7.17
Depreciation	3.71	3.52	3.89	4.20	5.23	5.99	8.09	7.86	9.30	9.94
Profit Before Tax	18	13	16	20	21	26	41	45	47	39
Tax %	19.48	18.95	18.16	19.81	13.10	20.05	25.89	24.71	22.64	22.83
Net Profit	14	11	13	16	18	21	30	34	37	30
EPS in Rs	—	—	3.92	5.04	3.81	4.60	6.54	7.29	7.96	—

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	14	35	215	398	692
Expenses	12	23	173	309	487
Operating Profit	1.95	13	42	90	205
OPM %	13.78	35.85	19.39	22.52	29.60
Other Income	0.46	3.68	2.82	19	30
Interest	0.57	2.14	9.45	22	27
Depreciation	0.71	1.78	10	17	35
Profit Before Tax	0.00	0.00	0.00	71	172
Tax %	13.30	32.19	-31.13	17.33	23.99
Net Profit	0.99	8.43	33	58	131
EPS in Rs	—	—	—	—	26.39
Dividend Payout %	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	8.74	9.82	31	46
Reserves	28	36	174	740
Borrowings	15	63	258	315
Other Liabilities	7.81	23	160	126
Total Liabilities	59	131	622	1,227
Fixed Assets	6.90	27	235	301
CWIP	8.06	34	97	173
Investments	15	16	0.01	0.01
Other Assets	29	53	289	754
Total Assets	59	131	622	1,227

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-10	-1.08	-20	-46
Cash from Investing Activity	-24	-48	-54	-429
Cash from Financing Activity	36	46	87	573
Net Cash Flow	1.58	-3.12	13	98

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jul 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	66.66%	45.76%	45.76%	45.77%	45.78%	45.80%	45.80%	45.82%	45.82%
FIIs	0.00%	5.51%	5.51%	4.17%	3.67%	4.28%	3.35%	3.64%	6.62%
DIIs	33.34%	18.61%	18.61%	9.65%	9.51%	8.61%	9.31%	9.61%	9.77%
Public	0.00%	30.11%	30.11%	40.40%	41.04%	41.31%	41.54%	40.93%	37.79%
Total Shareholders	177	43,707	43,707	37,653	36,389	34,917	34,401	34,126	36,498

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q1 FY27

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q3 FY25

Actions

Action Type

‌
‌

Announcements

Last 7 days

Sentiment

Earnings Call/Transcript

15 hours ago

Senores Pharmaceuticals: Earnings Call Audio Available

Senores Pharmaceuticals Ltd: audio recording of the earnings conference call for quarter ended June 30, 2026, held on July 27, 2026, is available on the company website.

Earnings Call/Transcript

15 hours ago

Senores Pharmaceuticals: Q1 FY27 Earnings Call Audio

Senores Pharmaceuticals informs that the audio recording of its earnings conference call on the unaudited results for quarter ended June 30, 2026 (held on July 27, 2026) is available on the company's website.

Regulatory/Compliance Filing

16 hours ago

Senores Pharmaceuticals: No Deviation in Fund Utilisation

Senores Pharmaceuticals Ltd submitted statement for quarter ended Jun 30, 2026 confirming no deviation in utilisation of Rs.95.00 Cr raised via preferential issue of 11,70,000 convertible equity warrants. Reviewed by Audit Committee and Board on July 27, 2026.

Regulatory/Compliance Filing

16 hours ago

Senores Pharmaceuticals: No Deviation in Preferential Funds

Senores Pharmaceuticals Ltd submitted statement for the quarter ended 2026-06-30 confirming no deviation in utilisation of Rs.95,00,40,000 raised via preferential issue of 11,70,000 convertible warrants. Reviewed by Audit Committee and Board on 2026-07-27.

Regulatory/Compliance Filing

16 hours ago

Senores Pharmaceuticals: Statement on IPO Fund Utilisation

Senores Pharmaceuticals submitted its statement of deviation/variation in utilisation of IPO proceeds for quarter ended June 30, 2026, reporting no deviation; reviewed by the Audit Committee and approved by the Board on July 27, 2026.

Regulatory/Compliance Filing

16 hours ago

Senores Pharmaceuticals: No Deviation in IPO Funds

Senores Pharmaceuticals Ltd submitted the statement of deviation/variation for quarter ended 2026-06-30 confirming no deviation in utilisation of IPO proceeds; reviewed by Audit Committee and Board on 2026-07-27 and uploaded on website.

Showing 1 - 6 of 22

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd (SENORES) is currently trading at 1,313.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Senores Pharmaceuticals Limited primarily engages in developing and manufacturing pharmaceuticals for regulated markets such as the US and Canada, along with emerging markets. It has built a robust regimen of ANDAs, facilitating entry in niche, high-complexity therapeutic areas. Significantly increased its portfolio to 46 approved ANDAs covering 137 strengths, reflecting a scaling up of operations and strategic market penetration. Expected launches from pending ANDAs promise further growth. The acquisition of a 75% stake in Apnar Pharmaceuticals has strengthened Senores' operational footprint in regulated markets, with benefits of existing approvals for generic formulations. The company has shown tremendous financial growth, evidenced by a 64% increase in total income in Q3FY26 YoY, supported by a focused strategy on regulated and emerging markets. Senores merges traditional pharma with modern strategies such as CDMO/CMO, optimizing both generic and branded sectors with increasing EBITDA margins through focused commercial plans.

Over the past 52 weeks, Senores Pharmaceuticals Ltd has traded between a low of ₹631.00 and a high of ₹1,509.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Senores Pharmaceuticals Ltd has a market capitalization of approximately 6,500.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Senores Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 56.34 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 6,500.46 Cr, Senores Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Senores Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Senores Pharmaceuticals Ltd is 56.34. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The company reported consolidated total income of ₹138.0 crore in Q1 FY26, up 72% year-on-year, as stated in the provided release and investor highlights.

The results are expected in the July to August 2026 window (indicative), in line with the broader NSE and BSE results season for the quarter ended June 2026.

The Q1 FY27 earnings conference call is scheduled for Monday, July 27, 2026, at 5:15 PM IST.

The call is scheduled for July 27, 2026, starting at 05:15 PM IST to discuss the quarter ended June 30, 2026.

Senores Pharmaceuticals Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock more with professional

Peers

Price Chart Comparison